Journal of Clinical Endocrinology & Metabolism, Vol 70, 1136-1141, Copyright © 1990 by Endocrine Society

ARTICLES

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

GJ Gormley, E Stoner, RS Rittmaster, H Gregg, DL Thompson, KC Lasseter, PH Vlasses and EA Stein
Merck, Sharp, and Dohme Research Laboratories, Rahway, New Jersey 07065.

Finasteride, a 5 alpha-reductase inhibitor, was administered to normal male volunteers in a blinded placebo-controlled study at daily oral doses of 25, 50, and 100 mg for 11 days (part 1) and daily oral doses of 0.04, 0.12, 0.2, and 1.0 mg for 14 days (part 2). Results from part 1 showed a significant reduction in dihydrotestosterone (DHT) at all doses and a significant increase in both testosterone (T) and delta 4- androstenedione at the 50- and 100-mg doses. No change was seen in LH, FSH, cortisol, or estradiol levels. Serum lipids, including total cholesterol, low density lipoprotein, high density lipoprotein, and triglycerides were not affected by treatment. Results from part 2 again showed significant reduction in DHT at all doses. DHT levels returned to pretreatment values within 14 days of discontinuing treatment. Significant increases in T were observed only in the 1.0 mg group and only during the first 8 days of treatment. The T/DHT ratio increased with all doses and returned to baseline when drug was discontinued. The DHT metabolites and androstanediol glucuronide and androsterone glucuronide were significantly reduced at all doses. There were no significant adverse experiences reported during part 1 or 2. In conclusion, finasteride is well tolerated by normal volunteers and results in significant suppression of serum DHT at all doses tested.

This article has been cited by other articles:

				S. S Connolly and J. M Fitzpatrick Medical treatment of benign prostatic hyperplasia Postgrad. Med. J., February 1, 2007; 83(976): 73 - 78. [Abstract] [Full Text] [PDF]

				W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, and J. T. Dalton Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia Endocrinology, December 1, 2004; 145(12): 5420 - 5428. [Abstract] [Full Text] [PDF]

				R. V. Clark, D. J. Hermann, G. R. Cunningham, T. H. Wilson, B. B. Morrill, and S. Hobbs Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5{alpha}-Reductase Inhibitor J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2179 - 2184. [Abstract] [Full Text] [PDF]

				H. Vierhapper, P. Nowotny, H. Maier, and W. Waldhausl Production Rates of Dihydrotestosterone in Healthy Men and Women and in Men with Male Pattern Baldness: Determination by Stable Isotope/Dilution and Mass Spectrometry J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5762 - 5764. [Abstract] [Full Text] [PDF]

				J. A. Schnorr, M. J. Bray, and J. D. Veldhuis Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2600 - 2606. [Abstract] [Full Text] [PDF]

				F. W. George Androgen Metabolism in the Prostate of the Finasteride-Treated, Adult Rat: A Possible Explanation for the Differential Action of Testosterone and 5{alpha}-Dihydrotestosterone during Development of the Male Urogenital Tract Endocrinology, March 1, 1997; 138(3): 871 - 877. [Abstract] [Full Text] [PDF]

				R. S. Rittmaster Finasteride N. Engl. J. Med., January 13, 1994; 330(2): 120 - 125. [Full Text]